NCT00328588已完成2 期
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 主要终点
- Tumor response rate (CR+PR)
研究概览
简要总结
A study for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients previously treated with chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed non-small cell lung cancer.
- •Prior chemotherapy regimen(s) for lung cancer
排除标准
- •History of other malignancy in the last 5 years
- •Major surgery within the past 21 days
研究组 & 干预措施
1
Experimental
7 days continuous infusion
干预措施: YM155 (Drug)
结局指标
主要结局
Tumor response rate (CR+PR)
时间窗: In first 6 cycles
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNon Small Cell Lung CancerNCT02716311Intergroupe Francophone de Cancerologie Thoracique118
终止
2 期
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung CancerNon Small Cell Lung CancerNCT00509366Duke University101
招募中
1 期
Pentixafor Positron Emission Tomography Scan: A New Imaging Test for Staging in Non-small Cell Lung Canceron-small cell lung cancerCancer - Lung - Non small cellNon-small cell lung cancerACTRN12615001265561Oceanic Molecular Imaging30
招募中
2 期
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLCNon-small Cell Lung CancerNCT05878028Quanli Gao33
Unknown
2 期
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain MetastasesNon Small Cell Lung Cancer MetastaticNCT03732482Taizhou Hospital400